Results 221 to 230 of about 1,582,096 (296)

Applying machine learning to pharmacovigilance data: A proof‐of‐concept study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Machine learning (ML) applications in pharmacovigilance remain limited and underexplored. Using data from the French National pharmacovigilance database (FNPV), this proof‐of‐concept study aimed to assess the feasibility of using a ML algorithm—eXtreme Gradient Boosting (XGBoost)—combined with SHapley Additive exPlanations (SHAP) analysis, to ...
Romain Barus   +6 more
wiley   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu   +7 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

Bullying for Kidneys?

open access: yes, 1991
Wight, Jeremy
core  

Spatial transcriptomic analysis of kidney biopsies identifies activation of complement and SPP1 networks in <i>Staphylococcus</i> infection-associated glomerulonephritis. [PDF]

open access: yesFront Nephrol
Karaiskos S   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy